Improving the prognosis of ovarian cancer patients is a major challenge to scientists and clinicians. At a recent multidisciplinary meeting in Washington DC, advances in identification of precursor lesions, progress in disease biomarkers and animal models, the promise of nanotechnology, and strategies for manipulation of the innate and adaptive immune response offered prospects for real progress in this difficult-to-treat disease.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Mar 15 2006|
ASJC Scopus subject areas
- Cancer Research